Enhertu Goes Into High Gear With HER2-Low Breast Cancer Approval

 
• By Joseph Haas
  
FDA Approved
Enhertu use in HER2-low breast cancer may take off with FDA nod
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip